Concepedia

David M. Weinreich

DM

Statistics

Publications

33

Citations

9.5K

H-Index

29

Active since

2002

Affiliations

Regeneron (United States)(Current)

National Cancer Institute

Sanofi (United States)

Sanofi (France)

Amgen (United States)

David M. Weinreich is an author at Regeneron (United States) specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

2002–2023

33

Publications

33

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert, Joseph K. Han, Martin Desrosiers et al. · The Lancet · 2019 · 1.4K citations

, , +7

Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery

Giulio F. Paciotti, Lonnie D. Myer, David M. Weinreich et al. · Drug Delivery · 2004 · 1.2K citations

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 772 citations

, , +9

Evinacumab for Homozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp et al. · New England Journal of Medicine · 2020 · 707 citations · Full text

Rows per page

1–5 of 33